TY - JOUR
T1 - Efficacy of Liraglutide in a Real-Life Cohort
AU - Heymann, Anthony
AU - Maor, Yasmin
AU - Goldstein, Inbal
AU - Todorova, Lora
AU - Schertz-Sternberg, Perlit
AU - Karasik, Avraham
N1 - Publisher Copyright:
© 2014, The Author(s).
PY - 2014/6/1
Y1 - 2014/6/1
N2 - Methods: In this retrospective analysis from the Israeli Health Maintenance Organization Maccabi, of patients with T2DM, treated with liraglutide ≥6 months during 2011–2012, evaluations were performed at baseline and 6 months.Results: Insulin-naïve patients (n = 1,101) treated with liraglutide with at least one A1c or weight measurement were identified. In 933 patients with an additional A1c value after 6 months, A1c decreased by 9 mmol/mol (p < 0.0001, 95% CI 7–11) from 72 mmol/mol. In patients receiving >2 oral antidiabetic drugs (OADs) prior to liraglutide treatment (80.7% patients), A1c decreased by 7 mmol/mol, and in those receiving ≤2 OADs, by 12 mmol/mol. In 453 patients with baseline data available, weight decreased by 2.55 kg (p < 0.0001); 173 patients (38.18%) achieved ≥1% A1c reduction. Furthermore, 91 patients (20.1%) achieved National Institute for Health and Care Excellence (NICE) criteria (decreased A1c ≥1%; weight ≥3%). Weight reduction was marginally correlated with A1c reduction.Conclusions: Evidence from real-life use of liraglutide demonstrated clinical effects similar to those demonstrated in RCTs.Introduction: In the Liraglutide Effect and Action in Diabetes (LEAD) randomized clinical trials (RCTs) assessing liraglutide in type 2 diabetes mellitus (T2DM), glycated hemoglobin (A1c) was reduced by 7–16 mmol/mol and weight by up to 3.4 kg. As real-life efficacy data on liraglutide is limited, the authors assessed clinical effects in a real-life cohort.
AB - Methods: In this retrospective analysis from the Israeli Health Maintenance Organization Maccabi, of patients with T2DM, treated with liraglutide ≥6 months during 2011–2012, evaluations were performed at baseline and 6 months.Results: Insulin-naïve patients (n = 1,101) treated with liraglutide with at least one A1c or weight measurement were identified. In 933 patients with an additional A1c value after 6 months, A1c decreased by 9 mmol/mol (p < 0.0001, 95% CI 7–11) from 72 mmol/mol. In patients receiving >2 oral antidiabetic drugs (OADs) prior to liraglutide treatment (80.7% patients), A1c decreased by 7 mmol/mol, and in those receiving ≤2 OADs, by 12 mmol/mol. In 453 patients with baseline data available, weight decreased by 2.55 kg (p < 0.0001); 173 patients (38.18%) achieved ≥1% A1c reduction. Furthermore, 91 patients (20.1%) achieved National Institute for Health and Care Excellence (NICE) criteria (decreased A1c ≥1%; weight ≥3%). Weight reduction was marginally correlated with A1c reduction.Conclusions: Evidence from real-life use of liraglutide demonstrated clinical effects similar to those demonstrated in RCTs.Introduction: In the Liraglutide Effect and Action in Diabetes (LEAD) randomized clinical trials (RCTs) assessing liraglutide in type 2 diabetes mellitus (T2DM), glycated hemoglobin (A1c) was reduced by 7–16 mmol/mol and weight by up to 3.4 kg. As real-life efficacy data on liraglutide is limited, the authors assessed clinical effects in a real-life cohort.
KW - Clinical effectiveness
KW - Diabetes
KW - Endocrinology
KW - Incretin
KW - Liraglutide
KW - Obesity
KW - Routine clinical practice
KW - Type 2 diabetes
UR - http://www.scopus.com/inward/record.url?scp=84922005537&partnerID=8YFLogxK
U2 - 10.1007/s13300-014-0062-2
DO - 10.1007/s13300-014-0062-2
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
AN - SCOPUS:84922005537
SN - 1869-6953
VL - 5
SP - 193
EP - 206
JO - Diabetes Therapy
JF - Diabetes Therapy
IS - 1
ER -
